Category: biotech

.Professional venture capital company venBio has raised an additional half a billion dollars to buy biotechs dealing with health conditions with unmet demand. The $528

.After announcing a period 3 launch based on good midstage results, iTeos as well as GSK are ultimately sharing the highlights coming from the phase

.Zevra Rehabs’ rare condition medication seems to be to become on the path to permission this autumn after getting the backing of an FDA consultatory

.Otsuka Pharmaceutical’s renal disease medication has reached the main endpoint of a phase 3 trial by showing in an interim analysis the decrease of patients’

.Bicara Therapeutics and also Zenas Biopharma have actually given fresh catalyst to the IPO market with filings that show what newly public biotechs might seem

.Chief executive officer David Ricks may find the firms putting together outdoors tents at basecamp behind Eli Lilly in an effort to get a hold

.After increasing $213 thousand in 2023– one of the year’s biggest private biotech rounds– Volume Biosciences is actually making cuts.” Regardless of our crystal clear

.As biotechs seek to switch a fresh webpage in August, at the very least 3 business have actually lost personnel in tries to shape on.

.OncoC4 is taking AcroImmune– and its internal scientific production abilities– under its wing in an all-stock merging.Both cancer biotechs were co-founded by OncoC4 chief executive

.Zephyrm Bioscience is gusting toward the Hong Kong stock market, submitting (PDF) for an IPO to money phase 3 trials of its own tissue therapy